BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Feb 14, 2011
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Qnaze beclomethasone dipropionate nasal aerosol: Phase III data

A double-blind, U.S. Phase III trial in 470 patients ages 12 and older showed that 320 µg/day Qnaze met the primary endpoint of significantly reducing reflective TNSS averaged over the 6-week treatment period from baseline vs. placebo (p<0.001). Qnaze also met the secondary...

Read the full 195 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >